Meningiomas – insights into genetics and correlations with histological features

Adriana Grigoraș, Laura Rîșcanu, Cornelia Amălinei


Meningiomas are the most common intracranial tumors. They occur more frequently in women and may be completely asymptomatic. According to the World Health Organization, the ability to invade and to develop recurrences represents the criterion which is used to designate three grades of meningiomas. In the last decade, advanced knowledges in genetics and molecular biology have improved our understanding of the clinical behavior of meningiomas. In addition to mutation or loss of NF2 gene, recurrent mutations of other genes, such as TERT, TRAF7, AKT1, AKT3, SMO, KLF4, SMARCE1, POLR2A, SUFU, BAP-1, PIK3CA, TSLC1, CDNK2A, PTCH1, TP73, PTEN, NDRG2, S6K, and CDNK2B have been identified within subsets of meningiomas. This review provides an overview and updates of the current knowledge of the genetics of meningioma in correlation with its histopathology. The insights into genetics and molecular profile of meningiomas may provide a valuable step towards developing new therapeutic approach for this type of intracranial tumor.


meningioma; meningothelial cells; WHO grade; NF2; gene mutations

Full Text:



Wiemels J, Wrensch M, Claus EB. Epidemiology and etiology of meningioma. J Neurooncol 2010; 99(3):307-314.

Simon M, Boström JP, Hartmann C. Molecular genetics of meningiomas: from basic research to potential clinical applications. Neurosurgery 2007; 60(5):787-98.

Bi WL, Zhang M, Wu WW, et al. Meningioma Genomics: Diagnostic, Prognostic, and Therapeutic Applications. Front Surg 2016; 3:40.

Yuzawa S, Nishihara H, Tanaka S. Genetic landscape of meningioma. Brain Tumor Pathol 2016; 33(4):237-247.

Bi WL, Abedalthagafi M, Horowitz P, et al. Genomic landscape of intracranial meningiomas. J Neurosurg 2016; 125(3):525-535.

Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348(6230):124-128.

Bi WL, Wu W, Santagata S, Reardon D, Dunn IF. Checkpoint inhibition in meningiomas. Immunotherapy 2016; 8(6):721-731.

Saraf S, McCarthy BJ, Villano JL. Update on meningiomas. Oncologist 2011; 16(11):1604-1613.

Buetow MP, Buetow PC, Smirniotopoulos JG. Typical, atypical, and misleading features in meningioma. Radiographics 1991; 11(6):1087-1106.

Lusins JO, Nakagawa H. Multiple meningiomas evaluated by computed tomography. Neurosurgery 1981; 9(2):137-141.

Ostrom QT, Gittleman H, Farah P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006–2010. Neuro Oncol 2013 15(Suppl. 2):ii1-56.

Kuratsu J, Kochi M, Ushio Y. Incidence and clinical features of asymptomatic meningiomas. J Neurosurg 2000; 92(5):766-770.

Goldstein RA, Jorden MA, Harsh IV. Meningiomas: Natural History, Diagnosis and Imaging. Philadelphia: Lippincott, Williams & Wilkins, 2005.

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO Classification of Tumours of the Central Nervous System. 5th edition. Lyon: IARC, 2016.

Dumitrescu GF, Indrei A, Husseini MEl, et al. Posterior fossa meningiomas: Correlation between site of origin and pathology. Rom Neurosurg 2010; 17:327–338.

Sanson MM, Cornu PP. Biology of meningiomas. Acta Neurochir 2000; 142(5):493-505.

Claus EB, Black PM, Bondy ML, et al. Exogenous hormone use and meningioma risk: what do we tell our patients? Cancer 2007; 110(3):471-476.

Bowers DC, Moskowitz CS, Chou JF, et al. Morbidity and mortality associated with meningioma after cranial radiotherapy: A report from the Childhood cancer survivor study. J Clin Oncol 2017; 35(14):1570-1576.

Yousaf II, Byrnes DP, Choudhari KA. Meningiomas induced by high dose cranial irradiation. Br J Neurosurg 2003; 17(3):219-225.

Neglia JP, Robison LL, Stovall MM, et al. New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2006; 98(21):1528-1537.

Meadows AT, Friedman DL, Neglia JP, et al. Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. J Clin Oncol 2009; 27(14):2356-2362.

Rodvall YY, Ahlbom AA, Pershagen GG, et al. Dental radiography after age 25 years, amalgam fillings and tumours of the central nervous system. Oral Oncol 1998; 34(4): 265-269.

Longstreth WT, Phillips LE, Drangsholt MM, et al. Dental X-rays and the risk of intracranial meningioma: a population-based casecontrol study. Cancer 2004; 100(5):1026–1034.

Blettner MM, Schlehofer BB, Samkange-Zeeb FF, et al. Medical exposure to ionising radiation and the risk of brain tumours: Interphone study group, Germany. Eur J Cancer 2007; 43(13):1990-1998.

Ribbert MW. Uber das endotheliom der dura. Virchows Arch 1910; 200:141-151.

Schmidt M. Uber die pachionischen granulationen und ihr verhältnis zu den sarcomen und psammomen der dura mater. Virchows Arch 1902; 170:429-469.

Okonkwo DO, Laws Jr ER. Meningiomas: Historical Perspective. In: Lee J.H. (eds) Meningiomas. Springer, London, 2009, 3-10.

Cushing H. The meningiomas (dural endotheliomas): their source and favored seats of origin (Cavendish Lecture). Brain 1922; 45:282-316.

al-Rodhan NR, Laws Jr ER. Meningioma: a historical study of the tumor and its surgical management. In: Al-Mefty O (ed). New York: Raven Press; 1991. 1-8.

Czarnetzki A, Schwaderer E, Pusch CM. Fossil record of meningioma. Lancet 2003; 362(9381):408.

Paterniti S. Meningiomas surgery in Italy in the nineteenth century: Historical review. Austin Neurosurg Open Access 2015; 2(2):1030.

Wang H, Lanzino G, Laws Jr ER. Meningioma: the soul of neurosurgery: historical review. Sem Neurosurg 2003; 14:163–168.

Bailey P, Bucy PC. The origin and nature of meningeal tumors. Am J Cancer 1931; 15:15-54.

Bujok J, Bienioszek M. Microcystic variant of an intraosseous meningioma in the frontal area: a case report. Case Rep Neurol Med 2014; 2014:527267.

Matano F, Adachi K, Murai Y, et al. Microcystic meningioma with late-phase accumulation on thallium-201 single-photon emission computed tomography: case report. Neurol Med Chir (Tokyo) 2014; 54(8):686-689.

Tan LT, Stewart CM, Sheerin F, et al. Ectopic orbital meningioma: Fact or fiction? Orbit 2017; 36(3):144-146.

Bayoumi AB, Laviv Y, Karaali CN, et al. Spinal meningiomas: 61 cases with predictors of early postoperative surgical outcomes. J Neurosurg Sci 2017. doi: 10.23736/S0390-5616.17.04102-9

Thompson LD, Gyure KA. Extracranial sinonasal tract meningiomas: a clinicopathologic study of 30 cases with a review of the literature. Am J Surg Pathol 2000; 24(5):640-650.

Suster S, Moran CA. Unusual manifestations of metastatic tumors to the lungs. Semin Diagn Pathol 1995; 12(2):193-206.

Ionescu D, Sasatomi E, Aldeeb D, et al. Pulmonary meningothelial-like nodules. A genotypic comparison with meningiomas. Am J Surg Pathol 2004; 28(2):207-214.

Burger PC, Scheithauer BW. Meningiomas. In: AFIP Atlas of Tumor Pathology: Tumors of the Central Nervous System. Washington, DC: American Registry of Pathology, 2007.

Cushing H, Eisenhardt L. Meningiomas: Their classification, regional behaviour, life history and surgical end results. Springfield, 1938.

Pamir N, Black P. Meningiomas: A Comprehensive Text. Elsevier, Philadelphia, 2010.

Harter PN, Braun Y, Plate KH. Classification of meningiomas-advances and controversies. Chin Clin Oncol 2017; 6(Suppl 1):S2.

Sahm F, Reuss DE, Giannini C. WHO 2016 Classification: changes and advancements in the diagnosis of miscellaneous primary CNS tumours. Neuropathol Appl Neurobiol 2018; 44(2):163-171. doi: 10.1111/nan.12397.

Marciscano AE, Stemmer-Rachamimov AO, Niemierko A, et al. Benign meningiomas (WHO Grade I) with atypical histological features: correlation of histopathological features with clinical outcomes. J Neurosurg 2016; 124(1):106-114.

Kapoor KG, Katz SE, Grzybowski DM, Lubow M. Cerebrospinal fluid outflow: an evolving perspective. Brain Res Bull 2008; 77(6):327-334.

Perry A, Gutmann DH, Reifenberger G. Molecular pathogenesis of meningiomas. J Neuroncol 2004; 70(2):183-202.

Striedinger K, VandenBerg SR, Baia GS, et al. The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP. Neoplasia 2008; 10(11):1204-1212.

McClatchey AI, Giovannini M. Membrane organization and tumorigenesis - the NF2 tumor suppressor, Merlin. Genes Dev 2005; 19(19):2265-2277.

Miller R Jr, DeCandio ML, Dixon-Mah Y, et al. Molecular targets and treatment of meningioma. J Neurol Neurosurg 2014; 1(1) pii: 1000101.

Li W, You L, Cooper J, et al. Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4 (DCAF1) in the nucleus. Cell 2010; 140(4):477-490.

Robb VA, Li W, Gascard P, et al. Identification of a third Protein 4.1 tumor suppressor, Protein 4.1R, in meningioma pathogenesis. Neurobiol Dis 2003; 13(3):191-202.

Pavelin S, Bečić K, Forempoher G, et al. The significance of immunohistochemical expression of Merlin, Ki-67, and p53 in meningiomas. Appl Immunohistochem Mol Morphol 2014; 22(1):46-49.

Dickinson PJ, Surace EI, Ca Leutenegger CM, et al. Expression of the tumor suppressor genes NF2, 4.1B, and TSLC1 in canine meningiomas. Vet Pathol 2009; 46(5):884-892.

Wang Z, Zhang J, Ye M, et al. Tumor suppressor role of protein 4.1B/DAL-1. Cell Mol Life Sci 2014; 71(24):4815-4830.

Pham MH, Zada G, Mosich GM, et al. Molecular genetics of meningiomas: a systematic review of the current literature and potential basis for future treatment paradigms. Neurosurg Focus 2011; 30(5):E7.

Shankar GM, Santagata S. BAP1 mutations in high-grade meningioma: implications for patient care. Neuro Oncol 2017; 19(11):1447-1456.

Clark VE, Harmancı AS, Bai H, et al. Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas. Nat Genet 2016; 48(10):1253-1259.

Sahm F, Daniel Schrimpf, Adriana Olar, et al. TERT Promoter mutations and risk of recurrence in meningioma. J Natl Cancer Inst 2016; 108(5):djv377.

Tang H, Zhu H, Wang X, et al. KLF4 is a tumor suppressor in anaplastic meningioma stem-like cells and human meningiomas. J Mol Cell Biol 2017; 9(4):315-324.

Abedalthagafi M, Bi WL, Aizer AA, et al. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro Oncol 2016; 18(5):649-655.

Clark VE, Erson-Omay EZ, Serin A, et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 2013; 339(6123):1077-1080.

Zadeh G, Karimi S, Aldape KD. PIK3CA mutations in meningioma. Neuro Oncol 2016; 18(5):603-4.

Mei Y, Bi WL, Greenwald NF, et al. Genomic profile of human meningioma cell lines. PLoS One 2017; 12(5):e0178322.

Reuss DE, Piro RM, Jones DT, et al. Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations. Acta Neuropathol 2013; 125(3):351-358.

Skiriute D, Tamasauskas S, Asmoniene V, et al. Tumor grade-related NDRG2 gene expression in primary and recurrent intracranial meningiomas. J Neurooncol 2011; 102(1):89-94.

Yakubov E, Ghoochani A, Buslei R, et al. Hidden association of Cowden syndrome, PTEN mutation and meningioma frequency. Oncoscience 2016; 3(5-6):149-155.

Kijima C, Miyashita T, Suzuki M, et al. Two cases of nevoid basal cell carcinoma syndrome associated with meningioma caused by a PTCH1 or SUFU germline mutation. Fam Cancer 2012; 11(4):565-570.

Surace EI, Lusis E, Haipek CA, Gutmann DH Functional significance of S6K overexpression in meningioma progression. Ann Neurol 2004; 56(2):295-298.

Smith MJ, Wallace AJ, Bennett C, et al. Germline SMARCE1 mutations predispose to both spinal and cranial clear cell meningiomas. J Pathol 2014; 234(4):436-40.

Abedalthagafi MS, Merrill PH, Bi WL, et al. Angiomatous meningiomas have a distinct genetic profile with multiple chromosomal polysomies including polysomy of chromosome 5. Oncotarget 2014; 5(21):10596-10606.

Ciurea ME, Georgescu AM, Purcaru SO, et al. Cancer stem cells: Biological functions and therapeutically targeting. Int J Mol Sci 2014; 15(5):8169-8185.

Galani V, Alexiou GA, Miliaras G, et al. Expression of Stem Cell Marker Nestin and MicroRNA-21 in Meningiomas. Turk Neurosurg 2015; 25(4):574-577.

Shivapathasundram G, Wickremesekera AC, Tan ST, Itinteang T. Tumour stem cells in meningioma: A review. J Clin Neurosci 2018; 47:66-71. doi: 10.1016/j.jocn.2017.10.059.

Negah SS, Aligholi H, Khaksar Z, et al. Survival, proliferation, and migration of human meningioma stem-like cells in a nanopeptide scaffold. Iran J Basic Med Sci 2016; 19(12): 1271-1278.


Copyright (c) 2018 Adriana Grigoraș, Laura Rîșcanu, Cornelia Amălinei

Creative Commons License
Archive of Clinical Cases is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


ISSN: 2360-6975